



PICI Global Immunotherapy Capacity Considerations

10 December 2020



What does “Innovative Cancer Medicines” mean?

Innovative (adj): featuring new methods; advanced and original

Medicines with current FDA approvals, that were considered include targeted therapies, immunotherapies, biologics impacting the standard of care for many tumor types

What's the problem being addressed?




Cancer care is progressing rapidly in select countries with advances leading to cures as well as prolonged and improved quality of life

Low- and middle-income countries (LMICs) do not have access to most of these critical, life-changing therapies

What's the approach?

CHALLENGE

When registered in the region,
sustainable access to the
therapeutic is needed



PROJECT TYPE

ACCESS

Demonstration of feasibility of
implementation is needed




DEMONSTRATION

So what is being done to get there?

Objective	Status
Identify Collaborators (Institute, Pharma, Governments, Academic)	✓
Establish Potential Therapeutics/Indications	✓
Assess Country Interests/Priorities/Sites	✓
Develop Capacity, Regulatory, Sustainability Metrics	✓
Assess readiness for demonstration project by hospital	✓
Select Initial Sites	✓
Request Potential Demonstration Projects	✓
Select Demonstration Projects	✓
Establish Costed Demonstration Project Plans	✓
Finalize Access and Demonstration Plans	<i>Pending</i>
Implementation	<i>Pending</i>

Which groups have come together to discuss this?



AstraZeneca

Bristol-Myers Squibb

Roche




*Collaborators span nine **countries**, three **pharma** companies, CHAI and PICI*

MOU 2018



Is cancer an issue in these countries?



Country	Incidence Top 10 Cancer Types** (# of Cases)	Mortality Top 10 Cancer Types** (# of Deaths)	Mortality / Incidence
Partner Countries	1088135	735693	0.68
United States of America	1234697	353671	0.29

*While recorded incidence of the top 10 cancer types in Partner Countries is ~90% that of the USA, **mortality is over 200% that of the United States***

Source: Globocan 2018

*Africa represents African Partners: Ethiopia, Kenya, Nigeria, Rwanda, South Africa, Tanzania, Uganda


**Top 10 cancer types by incidence in each country

Some therapeutics considered?

Manufacturer	Generic name
Astra Zeneca	Fulvestrant
	Olaparib
	Osimertinib
	Durvalumab
	Acalabrutinib
	Gefitinib
Bristol-Myers Squibb	Nivolumab
	Ipilimumab
Roche	Atezolizumab
	Trastuzumab
	Rituximab
	Bevacizumab
	Pertuzumab
	Ado-trastuzumab emtansine

*These **cancer medicines** have been shown to **improve patient outcomes** and have received **FDA approvals** across numerous tumor types*

Establishing a capacity assessment tool



Capacity assessment tool came together!

Introducing Innovative Cancer Medicines In Low and Middle Income Countries: Hospital Capacity Assessment Tool

Context and objectives of this capacity assessment:

This tool was developed in 2019 by the Parker Institute for Cancer Immunotherapy (PICI), the Clinton Health Access Initiative (CHAI), AstraZeneca (AZ), Bristol-Myers Squibb (BMS) and Roche to support a project to partner with a group of countries in Africa and Asia to speed up introduction of cutting-edge cancer medicines, such as immunotherapies. The tool was developed and completed by 9 high performing cancer centers in sub-Saharan Africa, Vietnam, and India.

The assessment was designed to understand the current hospital capacity related to identifying and managing eligible patients with innovative cancer medicines and what the key gaps to address are.

Please work with key stakeholders in your hospital to fill out this assessment tool.

Instructions for this completing this capacity assessment tool:

There are 5 different sections to fill out. Please complete them all

Tab to fill out	Description
1 - Staff and Patient numbers	Overview of your number of staff and patient numbers
2 - Diagnostics & Monitoring	Overview of your testing, diagnostics capabilities
3 - Treatment	Overview of your essential treatment services
4 - Supporting Systems	Overview of supporting systems in place for holistic care
FYI - Medicines in Scope	Overview of drugs being considered in the scope of this program

Please fill out:

Date of Tool completion:

Contact Person Details (who filled this form):

Name:	<input type="text"/>
Position & Organization:	<input type="text"/>
email:	<input type="text"/>



Version April 2020



Capacity assessment tool components, design, and goals



Components:

1 - Staff and Patient numbers	Overview of your number of staff and patient numbers
2 - Diagnostics & Monitoring	Overview of your testing, diagnostics capabilities
3 - Treatment	Overview of your essential treatment services
4 - Supporting Systems	Overview of supporting systems in place for holistic care

Design: Constructed as an excel questionnaire to be filled out by key stakeholders within each hospital to, in detail, describe their specific institution

Goal: understand the current capacity at a specific hospital for identifying and managing eligible patients with innovative cancer medicines

Capacity assessment tool key considerations



- **Experience** with cancer care: staffing, expertise, patient numbers
- Availability of **diagnostics**: pathology, lab, radiology, procedures
- Accessibility of **treatments**: standard of care, supportive, AE
- Presence of **supporting systems**: patient transport, follow up, data systems
- **Feasibility**: current practices, patient needs, indication(s) of interest

How were potential sites and projects identified?



Country

- Dedicated discussions with countries on their needs and preferences were conducted



Pharma


- Interests and priorities were established



Institute

- Indications, capacity, patient selection strategy were reviewed

Next Steps



PICI, CHAI, three pharmaceutical companies, and nine countries have come together to discuss enabling sustainable and efficacious administration of innovative cancer therapies in low and middle-income settings

